Background -Airway responsiveness to histamine and methacholine, direct smooth muscle spasmogens, is increased following inhalation of allergen. Although the aetiology of this phenomenon is unclear, increased cellular or neural activity may be involved since allergen also induces increases in airway responsiveness to the mast cell stimulus adenosine 5'-monophosphate (AMP) and the neural stimulus bradykinin. Methods -To explore this further, the airway responsiveness to sodium metabisulphite (MBS), an indirect neural stimulus with similar characteristics to bradykinin, was compared in 18 mild steroidnaive asthmatic subjects with the airway responsiveness to histamine before and after allergen challenge with extracts of house dust mite, grass pollen, or cat. All subjects inhaled doubling increments of histamine and MBS until the concentration provoking a 20% fall in forced expiratory volume in one second (PC20) was reached before and three hours after allergen challenge. Twelve of the subjects had additional challenges at 24 hours after the allergen. Results -Following allergen challenge all subjects showed an early response and 14 also had a late asthmatic response. For histamine there was a significant increase in airway responsiveness at both three and 24 hours compared with values before the allergen (0.89 (0.25) and 1.53 (0.52) doubling dose changes, respectively). In contrast, airway responsiveness to MBS was unaltered by allergen challenge (0.29 (0.27) and -0.33 (0.28) doubling dose changes compared with pre-allergen values at three and 24 hours, respectively). Conclusion -These data suggest that activation of airway sensory nerves is unlikely to contribute to the increase in airway responsiveness following inhalation of allergen. The previously observed allergen induced increase in airway responsiveness to bradykinin and AMP may involve non-neural pathways.
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Increased airway responsiveness is a characteristic feature of asthma.' The degree of bronchial hyperresponsiveness correlates with disease severity and the need for treatment. 2 Exposure to allergen provokes increased airway responsiveness to several bronchoconstrictor stimuli.34 Airway responsiveness to histamine or methacholine, both of which act directly on airway smooth muscle, is increased following allergen challenge and may persist for more than 72 hours.56 Changes in airway responsiveness to indirect acting bronchoconstrictor stimuli are less predictable. Airway responsiveness to bradykinin, a neural stimulus, is increased and sustained following allergen challenge,7 whereas bronchial reactivity to adenosine 5'-monophosphate (AMP), a mast cell stimulus, is increased at three but not at 24 hours after allergen challenge.6
The pathogenesis of increased airway responsiveness is unclear, in particular the relationship between airway responsiveness and airway inflammation induced by allergen exposure. ' The development ofthe late asthmatic response (LAR) following allergen challenge is dependent upon a complex series of changes in humoral and cellular immune mechanisms resulting in mucosal damage and oedema with infiltration of eosinophils and lymphocytes.34
These cells release mediators of inflammation such as cytokines and leukotrienes which not only perpetuate the inflammatory process by recruiting further inflammatory cells but also have direct effects on resident airway cells, mast cells, smooth muscle, and airway nerves that may underlie the changes in airway responsiveness. Thus, allergen induced airway inflammation may result in increased airway responsiveness to both direct and indirect stimuli.
Indirect bronchoconstriction following bradykinin and AMP appears to be specific for asthma and may be a more relevant measurement of airway responsiveness in asthmatic patients than non-specific challenge with histamine or methacholine." The greater increases in airway responsiveness to bradykinin than methacholine following allergen challenge suggest that upregulation ofneural reflexes may occur as a consequence of allergen induced inflammation.8 To examine this further we have compared the effect of allergen challenge on airway responsiveness to another indirect spasmogen, metabisulphite (MBS), with airway responsiveness to histamine, a direct spasmogen. MBS provokes cough and bronchoconstriction, suggesting an effect via airway sensory nerves, and exhibits similar characteristics to bradykinin." This study was de- The study was conducted in two phases: phase 1 involved a crossover study measuring airway responsiveness to histamine and MBS before and after both allergen and methacholine control challenges and phase 2 involved measurements of airway responsiveness to histamine and MBS before and after allergen challenge alone ( fig 1) .
Phase 1
Six subjects attended for two study days, each of 11 hours maximum duration and separated by a period of 21 days. On each occasion they were challenged with either allergen or methacholine (which served as a physiological control). Measurements of airway responsiveness to MBS and histamine were made before and after these challenges. The time points for the measurements of airway responsiveness were at two and one hours before and three and four hours after the allergen/control challenge. The order of the study days (that is, allergen or methacholine) was randomised for all subjects. The sequence ofMBS and histamine inhalation was the same for each subject on both study days. Each individual was therefore randomised to one of two groups determining the order of the stimuli. Three patients received histamine challenges before MBS -that is, two hours before and three hours after the challengeand the remaining three patients received MBS challenge first at each time point. Both before and after allergen challenge histamine and MBS challenges were only performed if the FEVI had recovered to within 10% of the baseline value.
Control and allergen challenges were administered in a single blind manner. Histamine and MBS challenges were performed by an independent operator (LJC) who remained blinded to allergen or control challenges.
On both study days measurements of FEV, were recorded for a maximum of eight hours after allergen/control challenges. Before leaving the unit all subjects received nebulised budesonide 2 mg and, if required, nebulised salbutamol 2.5 mg.
Phase 2 During phase 2 a further 12 subjects attended for one study day and were admitted overnight to the unit for at least 28 hours. Measurements of airway responsiveness to MBS and histamine were made at two and one hours before and at three and four hours after allergen challenge in a similar manner to phase 1 and, additionally, at 24 and 25 hours after allergen challenge. As in phase 1, each individual was randomly allocated to one of two groups defining the sequence in which histamine and MBS challenges were done. Allergen challenges were administered by the attending physician in an open manner who also administered the preallergen histamine and MBS challenges. The challenges at three and four hours and 24 and 25 hours after allergen were performed by an independent observer (LJC) who remained blinded to the pre-allergen PC20 data. As in phase 1, at all time points histamine and MBS challenges were only performed if the FEV, had recovered to within 10% of the baseline value.
Measurements of FEV, were made half hourly for 4-10 hours and hourly thereafter prior to undergoing further airway responsiveness measurements at 24 and 25 hours after allergen challenge. After the final challenge, before leaving the unit, all subjects received nebulised budesonide 2 mg and nebulised salbutamol 2.5 mg.
MATERIALS
On each study day fresh solutions of methacholine, histamine, MBS, (Sigma Chemicals, Poole, UK) and allergen (Aquagen SQ, ALK, Horsholm, Denmark) were made in 0.9% saline. The concentration ranges for methacholine and histamine were 0.03-32 mg/ml and for MBS 0.063-160 mg/ml. Freeze dried allergen extracts were used to make dilutions from a stock solution of 100 000 IU/ml to give final concentrations of 200, 1000, 2500, 5000, 12500, 25000, and 50000IU/ml. The allergen used for each subject was predicted by the response to skin prick testing. MEASUREMENT In a similar manner to the allergen challenge, measurements of FEV, were recorded five and 10 minutes after inhalation of serial increments of methacholine. The challenge was terminated when a fall in FEV1 of .25% from the postsaline value was observed. To maintain subject blindness, methacholine was administered in fourfold increments to provide challenge conditions similar to the allergen day in terms of both the number of doses delivered and the degree of bronchoconstriction experienced.
ANALYSIS OF DATA
All airway data are expressed as means (SE) except the PC20 data which were expressed as geometric means. The extent of the LAR was assessed as the maximal fall in FEV1 from baseline and expressed as percentage change.
All PC20 values were log transformed for analysis.
The effect of allergen on airway responsiveness to both histamine and MBS was expressed in terms of doubling dose changes and calculated using the formula:
[log10PC20(pre-allergen) -log10PC20 (postallergen)]/1ogl02 where the post-allergen PC20 was either three or 24 hours after challenge.
All data were analysed using the Student's t test for matched pairs, a p value of <0.05 being considered significant. In both phases all 18 subjects tolerated the acute allergen response well and demonstrated an EAR (mean maximum fall in FEV, of 32.8 (3.9)%). The mean maximum percentage fall in FEV, for EAR was similar for single and dual responders (table 1) .
In phase 1 all six subjects experienced equivalent acute bronchoconstriction following allergen and control challenge; after allergen the mean maximum fall in FEV, was 33.5 (3.6) %; after methacholine the mean maximum fall in FEV, was 36.1 (4.5)%. All subjects showed an LAR after allergen challenge. In phase 1 the maximum fall in the FEVy during the LAR is not defined as each subject received a bronchodilator once they fulfilled the criteria for the late response. On the control day no subject experienced bronchoconstriction between five and eight hours.
In phase 2 eight of the 12 subjects experienced an LAR with a mean maximum fall in FEVy of 25.3 (2.6)%. The four subjects who did not show an LAR had a mean maximum fall in FEVy of 9.0 (1.6)% 4-10 hours after allergen challenge (table 1) .
AIRWAY RESPONSIVENESS AFTER ALLERGEN
In phase 1 all six subjects completed the protocol. In phase 2 nine of the 12 subjects completed the protocol in full.
From phase 2 incomplete data are presented on two subjects showing LAR. Subject 12 had a prolonged EAR and was not within 10% of baseline FEV, at 3-4 hours. Subject 13 had not recovered to within 10% of baseline FEVy for a three hour post-allergen MBS challenge and had a profound LAR precluding any challenge at 24 and 25 hours. One of the four subjects without an LAR (no. 15) failed to recover to within 10% of baseline FEV1 following MBS challenge and therefore did not undergo histamine challenges at any time point. In addition, he developed a profound LAR and was not challenged at 24-25 hours.
In the two phases combined evaluable data were available on 16 subjects (nos 1-11, 13, 14, and 16-18) for a comparison of airway responsiveness to histamine before and three hours after allergen, and also on 16 subjects (nos 1-11 and 14-18) to compare airway responsiveness to MBS. In phase 2 data were available on 10 subjects to compare airway responsiveness to histamine (nos 7-12, 14, 16-18) and MBS (nos 7-12, 14, 16-18) before and 24 hours after allergen (table 2) .
For the group as a whole there was a significant increase in airway responsiveness to histamine challenge at both three and 24 hours following allergen challenge compared with the pre-allergen value (change in mean doubling dose 0.89 (0.25) at three hours (n = 16) and 1.53 (0.52) at 24 hours (n=10); p<0.05 at both time points; table 2, fig 2) . For subjects with an LAR the change in mean doubling dose was 0.95 (0.28) at three hours (n= 13) and 1.88 (0.62) at 24 hours (n=7); p<0.05 at both time points (table 2). The absence of an LAR did not significantly affect the result as Figure 3 Individual data showing log PC20 for six subjects undergoing sodium metabisulphite challenges before and three hours after allergen ch control challenge (methacholine).
two of the three subjects withou completed the protocol showed airway responsiveness to hista three and 24 hours ( Indeed, anti-inflammatory treatment with 14 days treatment of budesonide reduced airway responsiveness to methacholine and MBS by an equivalent one doubling dose, implying an inflammatory influence on smooth muscle responsiveness independent of an indirect airway action of MBS. 30 The results of our study may raise questions about the relative importance of neural factors in the aetiology of increased airway responsiveness following allergen challenge. Furthermore, we have demonstrated a clear distinction in airway responsiveness to two spasmogens with different airway actions, supporting the view that several mechanisms are involved in the pathogenesis of an allergen induced increase in airway responsiveness. Further studies comparing challenges with separate bronchoconstrictor actions may help to unravel these complex mechanisms.
